세계의 유방암 액체생검 검사 기기 시장 : 산업 규모, 점유율, 동향, 기회, 예측, 제공 품목별, 순환 바이오마커별, 용도별, 지역별, 경쟁별(2020-2030년)

Global Breast Cancer Liquid Biopsy Testing Devices Market was valued at USD 835.36 million in 2024 and is anticipated to project impressive growth in the forecast period with a CAGR of 17.20% through 2030. Liquid biopsy serves as a valuable asset in the realm of breast cancer diagnosis and treatment. The analysis of mutations through liquid biopsy aids in the identification of targeted therapies tailored to individual patients based on their tumor-specific genetic alterations. To illustrate, in the case of patients grappling with metastatic breast cancer, screening for the PIK3CA mutation, which is found in around 40% of HR-positive tumors, assists in determining the most effective treatment path. For instance, according to the American Society of Cancer (ASC) Report 2023, breast cancer remains the most common cancer among women in the United States, excluding skin cancers. It accounts for 30% of all female cancers diagnosed annually. In an effort to reduce the prevalence and mortality rates of breast cancer, the government has implemented policies and introduced laws to support patients with the costs of diagnosis and treatment. Also, according to the World Health Organization 2023 report, more than 2.3 million cases of breast cancer are diagnosed annually, making it the most prevalent cancer among adults. However, approximately 80% of breast cancer-related deaths occur in low- and middle-income countries.

Key Market Drivers

Advancements in Cancer Detection Technology

The landscape of cancer detection and diagnosis is evolving rapidly, and one area of remarkable progress is the development of liquid biopsy testing devices. These devices, which have gained prominence in the healthcare industry, are offering a non-invasive, highly sensitive, and patient-friendly approach to detect and monitor cancer, with breast cancer being a significant focus.

One of the keyways advancements in cancer detection technology are boosting the growth of the global breast cancer liquid biopsy market is by enhancing sensitivity and specificity. Liquid biopsies can now detect minute traces of circulating tumor DNA (ctDNA) or other biomarkers in a patient's bloodstream. This increased sensitivity ensures that even small tumors or minimal residual disease (MRD) can be detected accurately, which was often challenging with traditional diagnostic methods.

Key Market Challenges

Limited Sensitivity and Specificity

While liquid biopsy testing devices have advanced considerably, they may still face challenges related to sensitivity and specificity. Detecting circulating tumor DNA (ctDNA) or other biomarkers in the bloodstream can be challenging, especially for small or early-stage tumors. Improving the sensitivity and specificity of these tests remains a priority for the industry.

Key Market Trends

Integration with Conventional Diagnostics

The trend is moving towards the integration of liquid biopsy testing devices with traditional diagnostic methods. Combining liquid biopsies with imaging and tissue biopsies can provide a more comprehensive understanding of the disease. This integrated approach offers greater diagnostic accuracy and opens up new avenues for treatment decisions.

Key Market Players

• A Menarini AG
• NeoGenomics Laboratories Inc
• F Hoffmann-La Roche AG
• Myriad Genetics Inc
• QIAGEN NV
• Biocept Inc
• Sysmex Corp
• Fluxion Biosciences Inc
• Thermo Fisher Scientific Inc
• Epic Sciences Inc

Report Scope:

In this report, the Global Breast Cancer Liquid Biopsy Testing Devices Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Breast Cancer Liquid Biopsy Testing Devices Market, By Offerings:

• Assay & Reagents Kits
• Instruments

Breast Cancer Liquid Biopsy Testing Devices Market, By Circulating Biomarker:

• Circulating Tumor DNA
• Circulating Tumor Cell
• Extracellular Vesicles

Breast Cancer Liquid Biopsy Testing Devices Market, By Application:

• Cancer Applications
• Non-Cancer Applications

Breast Cancer Liquid Biopsy Testing Devices Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • Germany
  • United Kingdom
  • France
  • Italy
  • Spain
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Breast Cancer Liquid Biopsy Testing Devices Market.

Available Customizations:

Global Breast Cancer Liquid Biopsy Testing Devices market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 5.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 5.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 5.2.4. By Region
  • 5.2.5. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Offerings
  • 5.3.2. By Circulating Biomarker
  • 5.3.3. By Application
  • 5.3.4. By Region

6. North America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 6.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 6.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Offerings
      • 6.3.1.2.2. By Circulating Biomarker
      • 6.3.1.2.3. By Application
  • 6.3.2. Canada Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Offerings
      • 6.3.2.2.2. By Circulating Biomarker
      • 6.3.2.2.3. By Application
  • 6.3.3. Mexico Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Offerings
      • 6.3.3.2.2. By Circulating Biomarker
      • 6.3.3.2.3. By Application

7. Europe Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 7.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 7.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Offerings
      • 7.3.1.2.2. By Circulating Biomarker
      • 7.3.1.2.3. By Application
  • 7.3.2. United Kingdom Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Offerings
      • 7.3.2.2.2. By Circulating Biomarker
      • 7.3.2.2.3. By Application
  • 7.3.3. France Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Offerings
      • 7.3.3.2.2. By Circulating Biomarker
      • 7.3.3.2.3. By Application
  • 7.3.4. Italy Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Offerings
      • 7.3.4.2.2. By Circulating Biomarker
      • 7.3.4.2.3. By Application
  • 7.3.5. Spain Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Offerings
      • 7.3.5.2.2. By Circulating Biomarker
      • 7.3.5.2.3. By Application

8. Asia-Pacific Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 8.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 8.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Offerings
      • 8.3.1.2.2. By Circulating Biomarker
      • 8.3.1.2.3. By Application
  • 8.3.2. Japan Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Offerings
      • 8.3.2.2.2. By Circulating Biomarker
      • 8.3.2.2.3. By Application
  • 8.3.3. India Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Offerings
      • 8.3.3.2.2. By Circulating Biomarker
      • 8.3.3.2.3. By Application
  • 8.3.4. Australia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Offerings
      • 8.3.4.2.2. By Circulating Biomarker
      • 8.3.4.2.3. By Application
  • 8.3.5. South Korea Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Offerings
      • 8.3.5.2.2. By Circulating Biomarker
      • 8.3.5.2.3. By Application

9. South America Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 9.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 9.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Offerings
      • 9.3.1.2.2. By Circulating Biomarker
      • 9.3.1.2.3. By Application
  • 9.3.2. Argentina Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Offerings
      • 9.3.2.2.2. By Circulating Biomarker
      • 9.3.2.2.3. By Application
  • 9.3.3. Colombia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Offerings
      • 9.3.3.2.2. By Circulating Biomarker
      • 9.3.3.2.3. By Application

10. Middle East and Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Offerings (Assay & Reagents Kits, Instruments)
  • 10.2.2. By Circulating Biomarker (Circulating Tumor DNA, Circulating Tumor Cell, Extracellular Vesicles)
  • 10.2.3. By Application (Cancer Applications, Non-Cancer Applications)
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Offerings
      • 10.3.1.2.2. By Circulating Biomarker
      • 10.3.1.2.3. By Application
  • 10.3.2. Saudi Arabia Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Offerings
      • 10.3.2.2.2. By Circulating Biomarker
      • 10.3.2.2.3. By Application
  • 10.3.3. UAE Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Offerings
      • 10.3.3.2.2. By Circulating Biomarker
      • 10.3.3.2.3. By Application
  • 10.3.4. Kuwait Breast Cancer Liquid Biopsy Testing Devices Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Offerings
      • 10.3.4.2.2. By Circulating Biomarker
      • 10.3.4.2.3. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. A Menarini AG
• 14.2. NeoGenomics Laboratories Inc
• 14.3. F Hoffmann-La Roche AG
• 14.4. Myriad Genetics Inc
• 14.5. QIAGEN NV
• 14.6. Biocept Inc
• 14.7. Sysmex Corp
• 14.8. Fluxion Biosciences Inc
• 14.9. Thermo Fisher Scientific Inc
• 14.10. Epic Sciences Inc

15. Strategic Recommendations

16. About Us & Disclaimer